Quest Diagnostics (DGX) Shares Outstanding (Weighted Average) (2009 - 2026)

Quest Diagnostics has disclosed Shares Outstanding (Weighted Average) across 18 years of filings, most recently posting $110.0 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $110.0 million, down 0.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $110.0 million (down 0.9% YoY), and the FY2025 annual result was $111.0 million, changed 0.0% from the prior year.
• Shares Outstanding (Weighted Average) came in at $110.0 million for Q1 2026 at Quest Diagnostics, down from $111.0 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $119.0 million in Q1 2022 to a low of $110.0 million in Q1 2026.
• The 5-year median for Shares Outstanding (Weighted Average) is $112.0 million (2023), against an average of $112.7 million.
• Across the five-year window, Shares Outstanding (Weighted Average) slipped 10.53% in 2022 and grew 0.9% in 2025, its largest moves.
• Quest Diagnostics' Shares Outstanding (Weighted Average) stood at $116.0 million in 2022, then retreated by 3.45% to $112.0 million in 2023, then declined by 0.89% to $111.0 million in 2024, then changed by 0.0% to $111.0 million in 2025, then dropped by 0.9% to $110.0 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $110.0 million (Q1 2026), $111.0 million (Q4 2025), and $112.0 million (Q3 2025), per Business Quant data.